532 related articles for article (PubMed ID: 24634791)
1. Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.
Escors D
New J Sci; 2014 Jan; 2014():. PubMed ID: 24634791
[TBL] [Abstract][Full Text] [Related]
2. [Dendritic cells in cancer immunotherapy].
Gato M; Liechtenstein T; Blanco-Luquín I; Zudaire MI; Kochan G; Escors D
An Sist Sanit Navar; 2015; 38(2):279-87. PubMed ID: 26486534
[TBL] [Abstract][Full Text] [Related]
3. Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A's: Abundance, Activation and Antigen-Delivery.
Murgaski A; Bardet PMR; Arnouk SM; Clappaert EJ; Laoui D
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31091774
[TBL] [Abstract][Full Text] [Related]
4. Review: the application of dendritic cell-derived exosomes in tumour immunotherapy.
Quah B; O'Neill HC
Cancer Biother Radiopharm; 2000 Apr; 15(2):185-94. PubMed ID: 10803324
[TBL] [Abstract][Full Text] [Related]
5. The immunogenicity of dendritic cell-derived exosomes.
Quah BJ; O'Neill HC
Blood Cells Mol Dis; 2005; 35(2):94-110. PubMed ID: 15975838
[TBL] [Abstract][Full Text] [Related]
6. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy.
van Gulijk M; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2759. PubMed ID: 30568653
[TBL] [Abstract][Full Text] [Related]
7. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
Bossi G; Buisson S; Oates J; Jakobsen BK; Hassan NJ
Cancer Immunol Immunother; 2014 May; 63(5):437-48. PubMed ID: 24531387
[TBL] [Abstract][Full Text] [Related]
8. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
10. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
11. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells and their potential therapeutic role in haematological malignancy.
Kaminski ER; Goddard RV; Prentice AG
Leuk Lymphoma; 2003 Oct; 44(10):1657-66. PubMed ID: 14692516
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell therapy in cancer treatment; the state-of-the-art.
Sadeghzadeh M; Bornehdeli S; Mohahammadrezakhani H; Abolghasemi M; Poursaei E; Asadi M; Zafari V; Aghebati-Maleki L; Shanehbandi D
Life Sci; 2020 Aug; 254():117580. PubMed ID: 32205087
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
15. Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects.
Chang MC; Lee CN; Chen YL; Chiang YC; Sun WZ; Hu YH; Chen CA; Cheng WF
Clin Sci (Lond); 2012 Sep; 123(6):347-60. PubMed ID: 22264240
[TBL] [Abstract][Full Text] [Related]
16. Specific immunotherapy of cancer in elderly patients.
Matzku S; Zöller M
Drugs Aging; 2001; 18(9):639-64. PubMed ID: 11599633
[TBL] [Abstract][Full Text] [Related]
17. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.
Panya A; Thepmalee C; Sawasdee N; Sujjitjoon J; Phanthaphol N; Junking M; Wongkham S; Yenchitsomanus PT
Cancer Immunol Immunother; 2018 Oct; 67(10):1579-1588. PubMed ID: 30056600
[TBL] [Abstract][Full Text] [Related]
19. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
20. RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.
Tyagi RK; Mangal S; Garg N; Sharma PK
Expert Rev Anticancer Ther; 2009 Jan; 9(1):97-114. PubMed ID: 19105710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]